Hypercalcaemia--new mechanisms for old observations.

por Waxman, J.
Publicado 1990

Androgen resistance in prostate cancer

por Waxman, J, Ngan, S
Publicado 2008

Clues from hypercalcaemia

por Nicholson, S, Waxman, J
Publicado 2002

Osteoporosis and prostate cancer

por Dhillon, T, Waxman, J
Publicado 2003

The current status of scientific research and hormonal treatments for carcinoma of the prostate.

por Waxman, J., Saini, A.
Publicado 1991

COX inhibitors and breast cancer

por Mazhar, D, Ang, R, Waxman, J
Publicado 2006

Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer

por Michalaki, V, Syrigos, K, Charles, P, Waxman, J
Publicado 2004

Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer

por Michalaki, V, Syrigos, K, Charles, P, Waxman, J
Publicado 2004

Serum metalloproteinases and their inhibitors: markers for malignant potential.

por Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D., Waxman, J.
Publicado 1994

The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors.

por Qayum, A., Gullick, W., Clayton, R. C., Sikora, K., Waxman, J.
Publicado 1990

Circulating microRNAs as potential new biomarkers for prostate cancer

por Sita-Lumsden, A, Dart, D A, Waxman, J, Bevan, C L
Publicado 2013

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

por Papamichael, D., Gallagher, C. J., Oliver, R. T., Johnson, P. W., Waxman, J.
Publicado 1997

Macrophage-mediated breast cancer cell chemotaxis: the role of sphingosine kinase-1 activation

por Nunes, J, Sauer, L, Turner, J, Waxman, J, Sturge, J, Pshezhetskiy, D
Publicado 2010

Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer

por Kawano, Y, Diez, S, Uysal-Onganer, P, Darrington, R S, Waxman, J, Kypta, R M
Publicado 2009

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens

por Dart, D. A., Brooke, G. N., Sita-Lumsden, A., Waxman, J., Bevan, C. L.
Publicado 2011

Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection

por Nunes, J, Naymark, M, Sauer, L, Muhammad, A, Keun, H, Sturge, J, Stebbing, J, Waxman, J, Pchejetski, D
Publicado 2012

Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years.

por Oza, A. M., Ganesan, T. S., Dorreen, M., Johnson, P. W., Waxman, J., Gregory, W., Lim, J., Wright, J., Dadiotis, L., Barbounis, V.
Publicado 1992

Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer.

por Kalofonos, H. P., Sackier, J. M., Hatzistylianou, M., Pervez, S., Taylor-Papadimitriou, J., Waxman, J. H., Lavender, J. P., Wood, C., Epenetos, A. A.
Publicado 1989

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer

por Palmieri, C, Caley, M P, Purshouse, K, Fonseca, A-V, Rodriguez-Teja, M, Kogianni, G, Woodley, L, Odendaal, J, Elliott, K, Waxman, J, Sturge, J
Publicado 2013

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study

por Henry, N L, Pchejetski, D, A'Hern, R, Nguyen, A T, Charles, P, Waxman, J, Li, L, Storniolo, A M, Hayes, D F, Flockhart, D A, Stearns, V, Stebbing, J
Publicado 2010